Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 650.51
TGTX's Cash-to-Debt is ranked higher than
56% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. TGTX: 650.51 )
Ranked among companies with meaningful Cash-to-Debt only.
TGTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 650.51
Equity-to-Asset 0.66
TGTX's Equity-to-Asset is ranked higher than
50% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TGTX: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
TGTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.84 Max: 0.96
Current: 0.66
0.16
0.96
Piotroski F-Score: 3
Altman Z-Score: 13.55
Beneish M-Score: -5.36
WACC vs ROIC
19.50%
-586.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -51952.63
TGTX's Operating Margin % is ranked lower than
99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. TGTX: -51952.63 )
Ranked among companies with meaningful Operating Margin % only.
TGTX' s Operating Margin % Range Over the Past 10 Years
Min: -141552.63  Med: -41565.79 Max: -15109.21
Current: -51952.63
-141552.63
-15109.21
Net Margin % -51482.24
TGTX's Net Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. TGTX: -51482.24 )
Ranked among companies with meaningful Net Margin % only.
TGTX' s Net Margin % Range Over the Past 10 Years
Min: -95121.05  Med: -41413.82 Max: -13472.37
Current: -51482.24
-95121.05
-13472.37
ROE % -107.98
TGTX's ROE % is ranked lower than
81% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. TGTX: -107.98 )
Ranked among companies with meaningful ROE % only.
TGTX' s ROE % Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -107.98
-3919.22
-40.04
ROA % -89.17
TGTX's ROA % is ranked lower than
83% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. TGTX: -89.17 )
Ranked among companies with meaningful ROA % only.
TGTX' s ROA % Range Over the Past 10 Years
Min: -543.33  Med: -87.87 Max: 6.57
Current: -89.17
-543.33
6.57
ROC (Joel Greenblatt) % -6856.05
TGTX's ROC (Joel Greenblatt) % is ranked lower than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. TGTX: -6856.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TGTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -58800  Med: -17586.18 Max: -6856.05
Current: -6856.05
-58800
-6856.05
3-Year Revenue Growth Rate -20.60
TGTX's 3-Year Revenue Growth Rate is ranked lower than
75% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. TGTX: -20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TGTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: -20.6
0
44.2
3-Year EBITDA Growth Rate 28.00
TGTX's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. TGTX: 28.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TGTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -51.05 Max: 73
Current: 28
0
73
3-Year EPS without NRI Growth Rate 25.50
TGTX's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. TGTX: 25.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TGTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -42.75 Max: 76.5
Current: 25.5
0
76.5
GuruFocus has detected 4 Warning Signs with TG Therapeutics Inc $TGTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TGTX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TGTX Guru Trades in

Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q2 2016

TGTX Guru Trades in Q2 2016

Paul Tudor Jones 23,516 sh (New)
» More
Q3 2016

TGTX Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MGNX, NAS:OMER, NAS:PGNX, NAS:KERX, NAS:WVE, OTCPK:IPHYF, NAS:ANIK, NAS:BCRX, OTCPK:GNIIF, NAS:CTMX, OTCPK:MEOBF, NAS:RVNC, NAS:IMMU, NAS:VNDA, OTCPK:PHMMF, NAS:NDRM, NAS:NLNK, NAS:ITCI, NAS:JNCE, NYSE:MYOV » details
Traded in other countries:NKB2.Germany,
Headquarter Location:USA
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Top Ranked Articles about TG Therapeutics Inc

TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that preclinical data for the Company’s anti-PD-L1 monoclonal antibody, has been selected for presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.
The presentation details are as follows: • Title: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301  Abstract Number: 4606
Date and Time: Tuesday, April 4, 2017, 1:00 PM - 5:00 PM ET
Session: Immunoconjugates and Antibodies
Location: Halls A-C, Poster Section 26
Poster Number: 21
A copy of the above referenced abstract can be viewed online through the AACR meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. Cautionary Statement Some of the statements included in this press release, particularly those anticipating future clinical trials, timing of clinical trials for anti-PD-L1 antibodies and business prospects and potential uses for anti-PD-L1 antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to identify anti-PD-L1 antibodies suitable for clinical development, our ability to successfully and cost-effectively complete preclinical and clinical trials for anti-PD-L1 antibodies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior preclinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission.  Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. TGTX - G
CONTACT:
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference

Presentation Scheduled for Tuesday, March 21, 2017 at 3:20pm ET
NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare Conference, being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled to take place on Tuesday, March 21, 2017 at 3:20pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.TGTX - G
CONTACT:
Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference

Presentation Scheduled for Tuesday, March 14, 2017 at 3:00pm PT

NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 29th Annual ROTH Conference, being held at the Ritz Carlton in Laguna Niguel, California. The presentation is scheduled to take place on Tuesday, March 14, 2017 at 3:00pm PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. TGTX - G
CONTACT:
Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update
Company solidifies balance sheet with approximately $89M in gross proceeds through the combination of $57.5M public offering and $31M from at-the-market (ATM) sales facility completed prior to the offering
Investor conference call to be held today, Friday March 10, 2017 at 8:30am ET  NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2016 and provided recent company developments along with a business outlook for 2017.The Company announced that through the combination of an underwritten public offering, and proceeds raised through the utilization of an ATM program, the Company raised combined gross proceeds of approximately $89M before deducting underwriting discounts and commissions and other estimated offering expenses. The underwritten offering consisted of 5,128,206 shares of its common stock (plus a 30-day option to purchase up to an additional 769,230 shares of common stock, which has been exercised) at a price of $9.75 per share, with expected gross proceeds to TG Therapeutics of $57.5 million, less underwriting discounts and commissions. The offering is expected to close on or about March 14, 2017 subject to the satisfaction of customary closing conditions.  Prior to the public offering, the Company also issued approximately 3,000,000 shares through the ATM program for gross proceeds of approximately $31 million at an average price of $10.27, these shares were issued on March 9, 2017.Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, "2016 was a very productive year for the Company, laying the foundation for pivotal data read-outs in 2017 and 2018.  The first of which were reported earlier this week, with the announcement of the positive topline results from our Phase 3 GENUINE clinical trial.  For the remainder of 2017, we look forward to the full data presentation from the GENUINE trial in the summer and then in the second half to a meeting with the FDA to discuss a filing for accelerated approval.  All along we will continue to remain highly focused on enrolling into our proprietary UNITY programs, which are proceeding nicely and on schedule.” Mr. Weiss continued, “This week we also had the opportunity to solidify our cash reserves with the recently conducted offerings, which should provide us with sufficient capital to advance our key programs and get us closer to our goal of bringing our novel treatment options to patients with B-cell malignancies.”2016 Highlights Completed enrollment in our Phase 3 GENUINE clinical trial, which resulted in positive topline dataLaunched the UNITY-CLL Phase 3 and UNITY-DLBCL Phase 2b trials for the combination of TG-1101 TGR-1202Announced the positive outcome of our UNITY-CLL Phase 3 DSMB safety review meeting, pursuant to which the study was recommended to continue enrolling both front-line and previously treated patients with no changes recommended to the studyLaunched our first clinical trial in Multiple Sclerosis (MS) for TG-1101Announced the issuance of composition of matter patents for both TG-1101 and TGR-1202 providing protection through 2029 and 2033, respectively, both exclusive of available patent term extensionsAnnounced two publications in prestigious journals, the first in BLOOD describing a novel mechanism of TGR-1202 with potential in cMYC driven malignancies, and the second in the British Journal of Haematology with data from our Phase 2 clinical trial of TG-1101 plus ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL)Presented data at the ASH annual meeting including 3 oral presentations and 3 poster presentations, with a focus on combination therapyKey Objectives for 2017Present updated clinical data including the full Phase 3 GENUINE data at a major medical meeting in the first half of 2017Present clinical data from the Phase 2 Multiple Sclerosis (MS) trialInitiate a global Phase 3 trial in MSComplete the first interim analysis in the UNITY-CLL Phase 3 trialComplete the first interim analysis in the UNITY-DLBCL trialMeet with the FDA to review the GENUINE Phase 3 data and discuss suitability for filing for accelerated approvalPresent new and updated data from ongoing trials at various scientific meetings throughout the year, including the ASH annual meeting in DecemberFinancial Results for the Fourth Quarter and Full Year 2016Cash Position:  Cash, cash equivalents, investment securities, and interest receivable were $45.0 million as of December 31, 2016.  During the first quarter of 2017 the Company raised approximately $84 million of net proceeds from the underwritten public offering of the Company’s common stock and the utilization of the Company's at-the-market ("ATM") sales. 

R&D Expenses:  Research and development (R&D) expenses were $22.3 million and $69.2 million for the three and twelve months ended December 31, 2016, respectively, compared to $15.3 million and $47.7 million for the three and twelve months ended December 31, 2015, respectively. Included in research and development expenses for the three and twelve months ended December 31, 2016, are $9.1 million and $27.0 million, respectively, of manufacturing and CMC expenses for Phase 3 clinical trials and potential commercialization.  The increase in R&D expenses for both the three and twelve months ended December 31, 2016, is primarily due to the ongoing clinical development programs and related manufacturing costs for TG-1101 and TGR-1202. 

G&A Expenses:  General and administrative (G&A) expenses were $1.8 million and $9.9 million for the three and twelve months ended December 31, 2016, respectively, as compared to $2.4 million and $15.6 million for the three and twelve months ended December 31, 2015, respectively.  The period-over-period decrease in G&A expenses from three and twelve months ended December 31, 2015 relates primarily to non-cash compensation expenses related to equity incentive expense recognized during 2015. 

Net Loss:  Net loss was $23.7 million and $78.3 million for the three and twelve months ended December 31, 2016, respectively, compared to a net loss of $17.6 million and $62.9 million for the three and twelve months ended December 31, 2015, respectively.

Financial Guidance:  The Company believes its cash, cash equivalents, investment securities, and interest receivable on hand as of December 31, 2016 combined with the additional capital raised in the first quarter of 2017 will be sufficient to fund the Company’s planned operations for approximately the next 24 months.Conference Call Information The Company will host an investor conference call today, Friday, March 10, 2017 at 8:30am ET, to discuss the Company’s 2016 financial results and provide a business outlook for 2017.In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Year-End 2016 Earnings Call. A live audio webcast of this conference call will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.Cautionary StatementSome of the statements included in this press release, particularly those with respect to anticipating the timing of the completion of the GENUINE study, timing of presentation of the data for the GENUINE study, the timing of meeting with the FDA to discuss the GENUINE data, the usability of the results from GENUINE for accelerated approval, timing of initial data from the UNITY-DLBCL study, timing of the interim analysis from the UNITY-CLL, timing of the release of Phase 2 data and commencement of our MS pivotal program and the timing of how long our cash resources will carry the Company may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete the GENUINE, the UNITY-CLL or the UNITY-DLBCL trials; the risk that the clinical results from the GENUINE, UNITY-CLL and/or UNITY-DLBCL studies will be not positive and/or will not support regulatory approval of TG-1101 or TGR-1202; the risk that the FDA will not grant us a pre-BLA meeting to discuss the results of the GENUINE study; the risk that we will not file a BLA for TG-1101 or an NDA for TGR-1202 based on either the GENUINE or the UNITY-CLL; the risk that despite early positive trends in enrollment in the UNITY-CLL study that enrollment will be delayed beyond our projections; the risk that the planned interim analysis will not allow early closure of the single agent arms in the UNITY-CLL study, necessitating enrollment beyond the projected 450 patients, which would extend enrollment beyond our projections; the risk that safety issues or trends will be observed in the GENUINE study, the UNITY-CLL and/or the UNITY-DLBCL study that prevent approval of either TG-1101 and/or TGR-1202 or require us to terminate either the GENUINE study or the UNITY-CLL or the UNITY-DLBCL study prior to completion; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that the GENUINE study, as amended or the UNITY-CLL or the UNITY-DLBCL studies, or any of our other registration-directed clinical trials as designed or amended may not be sufficient or acceptable to support regulatory approval; the risk that trials will take longer to enroll than expected; the risk that the projected cost savings to be realized by amending the GENUINE trial will not be realized; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.TGTX - GTG Therapeutics, Inc.
Selected Consolidated Financial DataStatements of Operations Information (Unaudited): Three Months Ended December 31,Year Ended December 31,  2016 2015 2016 2015License revenue$   38,095 $  38,095 $  152,381 $  152,381      Costs and expenses:    Research and development:      Noncash compensation 868,624  1,528,296  2,742,354  4,261,406   Other research and development   21,414,723    13,725,926    66,489,820    43,445,817 Total research and development    22,283,347     15,254,222    69,232,174    47,707,223              General and administrative:              Noncash compensation 459,975  1,328,748  4,767,645  11,435,686   Other general and administrative    1,322,831     1,095,126    5,121,690    4,189,488 Total general and administrative   1,782,806    2,423,874    9,889,335    15,625,174      Total costs and expenses    24,066,153     17,678,096    79,121,509    63,332,397      Operating loss   (24,028,058)   (17,640,001)  (78,969,128)  (63,180,016)     Other (income) expense:      Interest income (57,576) (64,993) (323,032) (174,653) Other (income) expense    (296,339)    36,804    (393,202)   (56,717)Total other (income) expense    (353,915)    (28,189)   (716,234)   (231,370)     Net loss$  (23,674,143)$  (17,611,812)$(78,252,894)$(62,948,646)     Basic and diluted net loss per common share$   (0.48)$   (0.37)$   (1.60)$   (1.38)     Weighted average shares used in computing basic and diluted net loss per common share 49,278,068  48,127,335  49,041,354  45,646,414              Balance Sheet Information: December 31, 2016
(Unaudited) December 31, 2015Cash, cash equivalents, investment securities and interest receivable$  44,968,992  $  102,416,894 Total assets 54,781,547   113,473,201 Accumulated deficit (236,386,820)  (158,133,926)Total equity 35,867,802   101,573,302 

CONTACT:

Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock

NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the pricing of an underwritten public offering of 5,128,206 shares of its common stock at a price of $9.75 per share, with expected gross proceeds to TG Therapeutics of $50 million.  In addition, TG Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 769,230 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about March 14, 2017 subject to the satisfaction of customary closing conditions.    Jefferies LLC is acting as sole book-running manager for the offering. SunTrust Robinson Humphrey, Inc. and Ladenburg Thalmann & Co. Inc. are acting as lead managers.  H.C. Wainwright & Co., Aegis Capital Corp., Roth Capital Partners and OPN Capital Markets are acting as co-managers for the offering. TG Therapeutics intends to use the net proceeds of this offering to fund the ongoing development of TG-1101 and TGR-1202, to potentially in-license, acquire, develop and commercialize additional drug candidates, for research and development activities and for general corporate purposes. The offering is being made pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2014. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus related to the offering has been filed with the SEC and is available on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus, when available, may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, or by telephone at 877-821-7388, or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. Forward-Looking Statements Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: statements regarding the proposed public offering and the intended use of proceeds from the proposed offering; the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; market acceptance of our products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. TGTX-G 
Contact
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update

Investor Conference Call to be held Friday, March 10, 2017 at 8:30am ET

NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held tomorrow, Friday, March 10, 2017 at 8:30am ET to discuss results for the fourth quarter and year-end 2016, and provide a business outlook for 2017.  Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Year-End 2016 Earnings Call.  A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call. TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call. ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. TGTX-G
Contact
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ:TGTX), a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering will be offered by TG Therapeutics. In addition, TG Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.
Jefferies LLC is acting as sole book-running manager for the offering. TG Therapeutics intends to use the net proceeds of this offering to fund the ongoing development of TG-1101 and TGR-1202, to potentially in-license, acquire, develop and commercialize additional drug candidates, for research and development activities and for general corporate purposes. The offering is being made pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2014. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus related to the offering has been filed with the SEC and is available on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus, when available, may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, or by telephone at 877-821-7388, or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. Forward-Looking Statements Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: statements regarding the proposed public offering and the intended use of proceeds from the proposed offering; the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; market acceptance of our products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. TGTX-G
Contact
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 18.33
TGTX's PB Ratio is ranked lower than
93% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. TGTX: 18.33 )
Ranked among companies with meaningful PB Ratio only.
TGTX' s PB Ratio Range Over the Past 10 Years
Min: 2.51  Med: 6.28 Max: 20.69
Current: 18.33
2.51
20.69
PS Ratio 3000.00
TGTX's PS Ratio is ranked lower than
99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. TGTX: 3000.00 )
Ranked among companies with meaningful PS Ratio only.
TGTX' s PS Ratio Range Over the Past 10 Years
Min: 558.33  Med: 2042.5 Max: 4670
Current: 3000
558.33
4670
EV-to-EBIT -10.35
TGTX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. TGTX: -10.35 )
Ranked among companies with meaningful EV-to-EBIT only.
TGTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.5  Med: -6.5 Max: -0.6
Current: -10.35
-11.5
-0.6
EV-to-EBITDA -10.36
TGTX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. TGTX: -10.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
TGTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.5  Med: -6.5 Max: -0.6
Current: -10.36
-11.5
-0.6
Current Ratio 3.01
TGTX's Current Ratio is ranked lower than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. TGTX: 3.01 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 6.12 Max: 21.25
Current: 3.01
0.1
21.25
Quick Ratio 3.01
TGTX's Quick Ratio is ranked lower than
58% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. TGTX: 3.01 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 6.12 Max: 21.25
Current: 3.01
0.1
21.25
Days Sales Outstanding 201.71
TGTX's Days Sales Outstanding is ranked lower than
90% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. TGTX: 201.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 204.11 Max: 446.64
Current: 201.71
64.84
446.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.90
TGTX's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. TGTX: -16.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TGTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -851.2  Med: -21.45 Max: 0
Current: -16.9
-851.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 25.53
TGTX's Price-to-Net-Cash is ranked lower than
84% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. TGTX: 25.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TGTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.19  Med: 7.1 Max: 39.88
Current: 25.53
1.19
39.88
Price-to-Net-Current-Asset-Value 20.69
TGTX's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. TGTX: 20.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TGTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 7.04 Max: 32.06
Current: 20.69
1.18
32.06
Price-to-Tangible-Book 18.75
TGTX's Price-to-Tangible-Book is ranked lower than
89% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. TGTX: 18.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TGTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.65  Med: 6.45 Max: 28.78
Current: 18.75
0.65
28.78
Price-to-Median-PS-Value 1.47
TGTX's Price-to-Median-PS-Value is ranked lower than
74% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. TGTX: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TGTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.46 Max: 1.94
Current: 1.47
0.32
1.94
Earnings Yield (Greenblatt) % -9.66
TGTX's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. TGTX: -9.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TGTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3772.5  Med: 194.4 Max: 1470.1
Current: -9.66
-3772.5
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.60
Beta2.86
Short Percentage of Float34.83%
52-Week Range $4.10 - 15.05
Shares Outstanding (Mil)63.63

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 0 7
EPS ($) -1.61 -1.86
EPS without NRI ($) -1.61 -1.86
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neuro Apr 24 2017 
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of t Apr 20 2017 
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoc Apr 04 2017 
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for C Mar 20 2017 
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 17 2017 
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference Mar 13 2017 
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Upda Mar 10 2017 
TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock Mar 09 2017 
TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results Mar 09 2017 
TG Therapeutics Announces Proposed Public Offering of Common Stock Mar 08 2017 

More From Other Websites
Why TG Therapeutics Inc. Jumped Higher Today Apr 25 2017
Potential FDA Controversy Brewing For TG Therapeutics? Apr 25 2017
TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of... Apr 24 2017
Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics Apr 21 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of... Apr 20 2017
FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG... Apr 18 2017
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Apr 07 2017
TG Therapeutics stock rises 2% on preclinical data for cancer drug Apr 04 2017
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1... Apr 04 2017
3 Top Biotech Stocks to Buy in April Apr 03 2017
5 Top Performing Stocks of the Best ETF of Q1 Mar 30 2017
ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 Mar 27 2017
TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for... Mar 20 2017
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 17 2017
TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Mar 16 2017
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference Mar 13 2017
TG Therapeutics reports 4Q loss Mar 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)